{"id":2,"date":"2019-05-08T01:38:14","date_gmt":"2019-05-08T01:38:14","guid":{"rendered":"http:\/\/brinster.wpengine.com\/?page_id=2"},"modified":"2026-06-02T15:10:58","modified_gmt":"2026-06-02T15:10:58","slug":"sample-page","status":"publish","type":"page","link":"https:\/\/invest.fisherwallace.com\/","title":{"rendered":""},"content":{"rendered":"<section id=\"1_header\" class=\"wrap1\">\n<p>&nbsp;<\/p>\n<div class=\"breakwrap\">\n<div class=\"left\" style=\"padding-top: 35px;\">\n<div style=\"padding:56.25% 0 0 0;position:relative;\"><iframe src=\"https:\/\/player.vimeo.com\/video\/848518643?badge=0&amp;autopause=0&amp;player_id=0&amp;app_id=58479\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture; clipboard-write; encrypted-media; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" style=\"position:absolute;top:0;left:0;width:100%;height:100%;\" title=\"Logan &amp; Xenakis\"><\/iframe><\/div>\n<p><script src=\"https:\/\/player.vimeo.com\/api\/player.js\"><\/script><\/div>\n<div class=\"right\">\n<h2 style=\"font-weight: bold;\">Invest in Fisher Wallace Labs<\/h2>\n<h2 style=\"font-weight: bold;\">Neurotechnology for Mental Health and High Performance<\/h2>\n<p>Recent momentum:<\/p>\n<ul class=\"list\">\n<li class=\"list\">FDA Clearance application submitted in April 2026<\/li>\n<li class=\"list\">Pilot program launched in the U.S. Department of Veterans Affairs<\/li>\n<li class=\"list\">Invest $1502.90+ for Coupon Code for Free OAK (Rx will still be required)<\/li>\n<\/ul>\n<p>Invest $113+ to receive 100% Bonus Shares (i.e. buy 100 shares, receive a total of 200 shares);<\/p>\n<p>Invest $1502.90+ for Coupon Code for Free OAK (Rx will be required)<\/p>\n<table style=\"margin: 20px 0 0 0 !important;\">\n<tbody>\n<tr>\n<td style=\"width: 200px;\"><a class=\"investBtn\" href=\"https:\/\/fisherwallace.app.dealmaker.tech\/invitations\/d9ddea20-565d-4ecb-b5d1-9022e6a1c6ae\/view\">INVEST<\/a><\/td>\n<td>\n<p style=\"font-size: 15px;\">Share Price $11.21<br \/>\n($11.60 including 3.5% fee)<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1787792\/000178779226000005\/0001787792-26-000005-index.htm\" target=\"_blank\" rel=\"noopener\">SEC Filings<\/a>\u00a0|\u00a0<a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1787792\/000178779226000005\/fwofferingcircularcf11.pdf\" target=\"_blank\" rel=\"noopener\">Form C<\/a>\u00a0|\u00a0<a href=\"#12_faq\" >Investor Education<\/a>\n<\/div>\n<p><!--close left-->\n<\/div>\n<p><!--close breakwrap--><br \/>\n<br clear=\"all\"><br \/>\n<\/section>\n<section style=\"display:none;\" id=\"2_problems\" class=\"wrap1\">\n<div class=\"breakwrap\">\n<h1>Problems at Scale<\/h1>\n<p><\/p>\n<p><!--<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/LfdtzcWjd_I?rel=0;si=B0SoFomqAodsHDnI&amp;controls=0\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>--><img decoding=\"async\" class=\"corners\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/11\/adi_market.png\"><\/p>\n<p><a href=\"https:\/\/www.who.int\/news\/item\/02-09-2025-over-a-billion-people-living-with-mental-health-conditions-services-require-urgent-scale-up\" target=\"_blank\"><cite>Living with Mental Health Conditions<\/cite><\/a><br \/><a href=\"https:\/\/www.nami.org\/mental-health-by-the-numbers\/\" target=\"_blank\"><cite>Mental Health by the Numbers<\/cite><\/a><br \/><a href=\"https:\/\/news.va.gov\/137221\/va-2024-suicide-prevention-annual-report\/\" target=\"_blank\"><cite>Suicide Prevention Annual Report<\/cite><\/a><br \/>\n<!--\n\n<div class=\"flex-container2\">\n\n\n<div class=\"left\">\nAs many as 140 million Americans and 2.5 billion people globally have clinically significant symptoms of anxiety, depression and\/or insomnia.\n<\/div>\n\n\n\n\n<div class=\"right\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-232\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/iStock-2189360130.jpg\" alt=\"\" width=\"1255\" height=\"836\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/iStock-2189360130.jpg 1255w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/iStock-2189360130-300x200.jpg 300w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/iStock-2189360130-1024x682.jpg 1024w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/iStock-2189360130-768x512.jpg 768w\" sizes=\"auto, (max-width: 1255px) 100vw, 1255px\" \/><\/div>\n\n\n<\/div>\n\n-->\n<\/div>\n<p><!--close breakwrap--><br \/>\n<\/section>\n<section id=\"4_about\" class=\"wrap1\" style=\"background-color:hsl(198, 100%, 46%);color:white;\">\n<div class=\"breakwrap\">\n<div class=\"~flex-container2\" style=\"padding: 4% 0%;\">\n<h1>About Fisher Wallace<\/h1>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/oak_animation_latest.gif\" alt=\"\" width=\"1138\" height=\"638\" class=\"corners alignnone size-full wp-image-298\" \/><\/p>\n<p>The result of 17 years of R&#038;D, our wearable brain stimulation technology engages brain structures that govern mood, sleep, autonomic function, and cognitive resilience. Validated as effective in treating anxiety, depression, and insomnia, our Version 2.0 technology is positioned to go-to-market later this year pending FDA clearance. <\/p>\n<ul class=\"list\">\n<li class=\"list\">\u22482000 participants in randomized, controlled clinical trials and real-world studies<\/li>\n<li class=\"list\">60,000 active users of proof-of-concept device\n<li class=\"list\">14,000 proof-of-concept device prescribers<\/li>\n<li class=\"list\">Research partners include the U.S. Department of Veterans Affairs, Seattle Police Department, Harvard Medical School, and Massachusetts General Hospital.<\/li>\n<\/ul>\n<\/div>\n<\/section>\n<section id=\"3_use\">\n<h1>Use of Funds<\/h1>\n<p>Achieving our funding goal will enable us to complete OAK, manufacture inventory, hire key talent, market to government, employer and consumer channels, and secure the runway to profitability post FDA clearance.<\/p>\n<\/section>\n<section id=\"regulatory\" class=\"wrap1\">\n<div class=\"breakwrap\">\n<div class=\"\">\n<h1>Regulatory Targets<\/h1>\n<p>We are positioning OAK as a prescription mental health intervention first, and then as a preascription-grade tool for human performance:<\/p>\n<ul class=\"list\">\n<li class=\"list\">FDA Clearance for the treatment of anxiety &#8211; 2026<\/li>\n<li class=\"list\">FDA Approval for the acute treatment of depression in women &#8211; 2027<\/li>\n<li class=\"list\">FDA Clearance for the treatment of insomnia &#8211; 2027<\/li>\n<li class=\"list\">FDA Clearance (De Novo) to support autonomic function and\/or cognitive resilience in health individuals &#8211; 2027<\/li>\n<li class=\"list\">FDA Approval to treat depression in men &#8211; 2027\/2028<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p><!--close breakwrap--><br \/>\n<\/section>\n<p><!--\n\n<section id=\"regulatory\">\n\n\n<h1>Regulatory Targets<\/h1>\n\n\n\n\n<p>We are positioning OAK as a prescription mental health intervention first, and then as a preascription-grade tool for human performance:<\/p>\n\n\n\n\n<ul class=\"list\">\n\n\n<li class=\"list\">FDA Clearance for the treatment of anxiety - 2026<\/li>\n\n\n\n\n<li class=\"list\">FDA Approval for the acute treatment of depression in women - 2027<\/li>\n\n\n\n\n<li class=\"list\">FDA Clearance for the treatment of insomnia - 2027<\/li>\n\n\n\n\n<li class=\"list\">FDA Clearance (De Novo) to support autonomic function and\/or cognitive resilience in health individuals - 2027<\/li>\n\n\n\n\n<li class=\"list\">FDA Approval to treat depression in men - 2027\/2028<\/li>\n\n\n<\/ul>\n\n\n<\/section>\n\n--><br \/>\n<!--\n\n<section>\n\n\n<h1>Version 1.0 Metrics<\/h1>\n\n\n\n\n<div class=\"row\">\n\n\n<div class=\"col\">\n\n\n<h2>Active Users<\/h2>\n\n[countup start=\"0\" end=\"60000\" decimals=\"0\" duration=\"5\" suffix=\" +\" scroll=\"true\"]\n<\/div>\n\n\n\n\n<div class=\"col\">\n\n\n<h2>Gross Revenue<\/h2>\n\n[countup start=\"0\" end=\"40000000\" decimals=\"0\" duration=\"5\" prefix=\"$\" suffix=\" +\" scroll=\"true\"]\n<\/div>\n\n\n\n\n<div class=\"col\">\n\n\n<h2>Prescribers<\/h2>\n\n[countup start=\"0\" end=\"14000\" decimals=\"0\" duration=\"5\" suffix=\" +\" scroll=\"true\"]\n<\/div>\n\n\n<\/div>\n\n\n<\/section>\n\n--><\/p>\n<section id=\"5_scientific\">\n<div class=\"flex-container2\">\n<div class=\"left\">\n<h1>Business Model<\/h1>\n<p>Our business model centers on high-margin, scalable hardware with a smartphone-like upgrade cycle, sold across government, enterprise, and consumer markets. We are developing digital products, including recurring services. As future iterations of OAK integrate discreet, low-cost, ultra-high-fidelity sensors (not commercially available today), we expect brain activity monitoring at scale to compound the platform\u2019s value for all stakeholders.<\/p>\n<p>Under temporary FDA clearance (until 2023) we generated more than $40 million is sales of our proof-of-concept device. We are now preparing to launch our first fully realized product with significantly more leverage than before: government procurement and insurance reimbursement pathways, large-scale clinical evidence, institutional partnerships, world-class product design, and an installed base of 60,000 active users and 14,000 prescribers.<\/p>\n<\/div>\n<div class=\"right\"><img loading=\"lazy\" decoding=\"async\" class=\"corners\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/oak_exploded_latest-e1711467497556.jpeg\" alt=\"\" width=\"1408\" height=\"1080\" class=\"alignnone size-full wp-image-178\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/oak_exploded_latest-e1711467497556.jpeg 1408w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/oak_exploded_latest-e1711467497556-300x230.jpeg 300w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/oak_exploded_latest-e1711467497556-1024x785.jpeg 1024w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/oak_exploded_latest-e1711467497556-768x589.jpeg 768w\" sizes=\"auto, (max-width: 1408px) 100vw, 1408px\" \/><\/div>\n<\/div>\n<\/section>\n<section id=\"6_advancing\" class=\"wrap1\" style=\"~display:none;\">\n<div class=\"breakwrap\">\n<div class=\"flex-container2\">\n<div class=\"left\">\n<h1>Focus on Veterans, Warfighters, and First Responders<\/h1>\n<p>Our recent anxiety and stress study, conducted in collaboration with the Seattle Police Department, enrolled 164 first responders nationwide and serves as the primary evidence for our initial Version 2.0 FDA clearance application. Our device is also being tested within the U.S. Department of Veterans Affairs, with an active-duty PTSD treatment site joining as a second site. Dr. David Shulkin, former U.S. Secretary of Veterans Affairs, has served as a key advisor for the past two years.<\/p>\n<\/div>\n<div class=\"right\"><img decoding=\"async\" class=\"corners alignnone size-full wp-image-228\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/father_children.png\" alt=\"\"  \/><\/div>\n<\/div>\n<\/div>\n<p><!--close breakwrap--><br \/>\n<\/section>\n<section id=\"7_gen_z\">\n<div class=\"flex-container2\">\n<div class=\"left\">\n<h1>Track Record<\/h1>\n<p>Our CEO, Kelly Roman, generated over $40 million in proof-of-concept device sales under temporary FDA clearance before the technology had large-scale published clinical research, major institutional support, government procurement, insurance reimbursement, or industrial design from the teams behind Beats and Nest\u2014and without venture capital. Kelly joined cofounder Chip Fisher in 2009 and did not begin raising outside capital until launching equity crowdfunding in 2019. OAK\u2019s scale-up will benefit from multiple advantages the proof-of-concept device never had, which is why we expect a bright future ahead.<\/p>\n<\/div>\n<div class=\"right\"><!--<img decoding=\"async\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/oak_green.png\" alt=\"\" class=\"corners alignnone size-full wp-image-254\" \/><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/Screenshot-2024-03-26-at-9.21.01\u202fAM.png\" alt=\"\" width=\"1860\" height=\"2138\" class=\"corners alignnone size-full wp-image-179\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/Screenshot-2024-03-26-at-9.21.01\u202fAM.png 1860w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/Screenshot-2024-03-26-at-9.21.01\u202fAM-261x300.png 261w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/Screenshot-2024-03-26-at-9.21.01\u202fAM-891x1024.png 891w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/Screenshot-2024-03-26-at-9.21.01\u202fAM-768x883.png 768w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/Screenshot-2024-03-26-at-9.21.01\u202fAM-1336x1536.png 1336w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/03\/Screenshot-2024-03-26-at-9.21.01\u202fAM-1782x2048.png 1782w\" sizes=\"auto, (max-width: 1860px) 100vw, 1860px\" \/>--><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/OAK-02-2-scaled.jpg\" alt=\"\" width=\"2560\" height=\"1441\" class=\"alignnone size-full wp-image-303\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/OAK-02-2-scaled.jpg 2560w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/OAK-02-2-300x169.jpg 300w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/OAK-02-2-1024x576.jpg 1024w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/OAK-02-2-768x432.jpg 768w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/OAK-02-2-1536x864.jpg 1536w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/OAK-02-2-2048x1152.jpg 2048w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><\/div>\n<p><br clear=\"all\">\n<\/div>\n<p style=\"margin-bottom:0;\">&nbsp;<\/p>\n<\/section>\n<section id=\"8_interest\" class=\"wrap1\" style=\"background-color:hsl(198, 100%, 46%);color:white;\">\n<div class=\"breakwrap flex-container2\">\n<div class=\"left\">\n<h1>Join The Mission<\/h1>\n<p>The 60,000 active users of our proof-of-concept device have been responsible for funding our clinical research and product development, investing over $11 million via equity crowdfunding. We invite you to join the mission of improving mental healthcare and human performance with an investment of $113 or more. Dive deeper into our story on Substack: <a target=\"_blank\" href=\"https:\/\/open.substack.com\/pub\/kellyfisherwallace\/p\/the-race-for-human-intelligence?r=zqvr&#038;utm_campaign=post-expanded-share&#038;utm_medium=web\">An Affordable Mass of Cognitive Density<\/a>.<\/p>\n<\/div>\n<div class=\"right\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/fda_sm.jpg\" alt=\"\" width=\"500\" height=\"441\" class=\"alignnone size-full wp-image-302\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/fda_sm.jpg 500w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/05\/fda_sm-300x265.jpg 300w\" sizes=\"auto, (max-width: 500px) 100vw, 500px\" \/><\/div>\n<\/div>\n<p><br clear=\"all\">\n<\/div>\n<\/section>\n<section id=\"8_interest\" style=\"display:none;\">\n<div class=\"flex-container2\">\n<div class=\"left\">\n<h1>In the National Interest<\/h1>\n<p>Brain performance and resilience are essential to national security and public safety. As companies like Palantir and Anduril strengthen U.S. hardware and operational software capabilities across the defense and other sectors, Fisher Wallace is focused on strengthening human capabilities.<\/p>\n<p>Read the Substack by our Co-Founder and CEO, Kelly Roman<\/p>\n<p>We are currently scoping US contract manufacturing opportunities to manufacture devices for the US government. <\/p>\n<\/div>\n<div class=\"right\"><img decoding=\"async\" class=\"corners alignnone size-full wp-image-228\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/father_children.png\" alt=\"\"  \/><\/div>\n<\/div>\n<\/section>\n<section id=\"9_advisors\" class=\"wrap1\">\n<div class=\"breakwrap\">\n<h1>Advisors<\/h1>\n<div class=\"left\"><img loading=\"lazy\" decoding=\"async\" style=\"max-width:100%\" class=\"alignnone size-full wp-image-231\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/Dr.-Maurizio-Fava.jpg\" alt=\"\" width=\"460\" height=\"460\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/Dr.-Maurizio-Fava.jpg 460w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/Dr.-Maurizio-Fava-300x300.jpg 300w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/Dr.-Maurizio-Fava-150x150.jpg 150w\" sizes=\"auto, (max-width: 460px) 100vw, 460px\" \/><\/p>\n<p><strong>Dr. Maurizio Fava<\/strong><br \/>\nChair, Department of Psychiatry, Mass General Brigham | Psychiatrist-in-Chief, Massachusetts General Hospital | Slater Family Professor of Psychiatry, Harvard Medical School<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" style=\"max-width:100%;filter: grayscale(100%);\" class=\"alignnone size-full wp-image-230\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/shulkin_david-landscape_2-e1758813255924.jpg\" alt=\"\" width=\"460\" height=\"460\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/shulkin_david-landscape_2-e1758813255924.jpg 400w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/shulkin_david-landscape_2-e1758813255924-300x300.jpg 300w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/shulkin_david-landscape_2-e1758813255924-150x150.jpg 150w\" sizes=\"auto, (max-width: 460px) 100vw, 460px\" \/><\/p>\n<p><strong>Dr. David Shulkin<\/strong><br \/>\nNinth Secretary, U.S. Department of Veterans Affairs | Former VA Under Secretary for Health | Former Chief Executive, Beth Israel Medical Center and Morristown Medical Center<\/p>\n<\/div>\n<p><br clear=\"all\"><br \/>\n<!--close breakwrap--><br \/>\n<\/section>\n<section id=\"10_founders\">\n<h1>Co-Founders<\/h1>\n<p><img loading=\"lazy\" decoding=\"async\" style=\"max-width:100%\" class=\"alignnone size-full wp-image-141\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/kr.png\" alt=\"\" width=\"443\" height=\"512\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/kr.png 443w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/kr-260x300.png 260w\" sizes=\"auto, (max-width: 443px) 100vw, 443px\" \/><br \/>\n<strong>Kelly Roman<\/strong><br \/>\nCo-Founder and CEO<br \/>\n17 years of neurotech leadership, published author, Harvard College graduate, son of U.S. Army Veteran<br \/>\n<img loading=\"lazy\" decoding=\"async\" style=\"max-width:100%\" class=\"alignnone size-full wp-image-137\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/cf.png\" alt=\"\" width=\"400\" height=\"400\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/cf.png 400w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/cf-300x300.png 300w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/cf-150x150.png 150w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><br \/>\n<strong>Charles \u201cChip\u201d Fisher<\/strong><br \/>\nCo-Founder and Chairman<br \/>\nAngel investor in Fisher Wallace Labs, Philanthropist, Harvard College graduate, Juilliard Board Member\n<\/div>\n<\/section>\n<section id=\"12_faq\" class=\"wrap1\" style=\"scroll-margin-top:80px;\">\n<div class=\"breakwrap\">\n<h1>Frequently asked questions<\/h1>\n<div class=\"left\">\n<details>\n<summary>1. What is Fisher Wallace Lab\u2019s pre-money valuation?<\/summary>\n<p>Fisher Wallace Lab&#8217;s pre-money valuation is $120,500,000. The valuation was calculated by multiplying the total number of shares outstanding (TSO) by the price per share offered in this raise. This is a pre-money valuation \u2014 meaning it reflects the company&#8217;s value before any new funds raised in this offering are added.<\/p>\n<\/details>\n<details>\n<summary>2. Why invest in startups?<\/summary>\n<p>Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren\u2019t buying products or merchandise &#8211; you are buying a piece of a company and helping it grow.<\/p>\n<\/details>\n<details>\n<summary>3. How much can I invest?<\/summary>\n<p>Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.<\/p>\n<\/details>\n<details>\n<summary>4. How do I calculate my net worth?<\/summary>\n<p>To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person\u2019s primary residence). The resulting sum is your net worth.<\/p>\n<\/details>\n<details>\n<summary>5. What are the tax implications of an equity crowdfunding investment?<\/summary>\n<p>We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.<\/p>\n<\/details>\n<details>\n<summary>6. Who can invest in a Regulation CF Offering?<\/summary>\n<p>Individuals over 18 years of age can invest.<\/p>\n<\/details>\n<details>\n<summary>7. There will always be some risk involved when investing in a startup or small business.<\/summary>\n<p>The earlier you invest, the more risk that is usually present. If a company goes out of business, your ownership interest could lose all value. Your\u00a0shares may not have voting rights or you may have limited voting power to direct the company due to dilution over time. You may have to wait five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That\u2019s why startups should only be part of a more balanced, overall investment portfolio.<\/p>\n<\/details>\n<details>\n<summary>8. The Common Stock (the \u201cShares\u201d) of Fisher Wallace Laboratories (the \u201cCompany\u201d) is not publicly-traded.<\/summary>\n<p>As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: (i) the Company gets acquired by another company, or (ii) the Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return as a result of business failure. Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.<\/p>\n<\/details>\n<details>\n<summary>9. Exceptions to limitations on selling shares during the one-year lockup period:<\/summary>\n<p>In the event of death, divorce, or similar circumstance, shares can be transferred to:<br \/>\n\u2022 The company that issued the securities<br \/>\n\u2022 An accredited investor<br \/>\n\u2022 A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)<\/p>\n<\/details>\n<details>\n<summary>10. What happens if a company does not reach their funding target?<\/summary>\n<p>If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.<\/p>\n<\/details>\n<details>\n<summary>11. How can I learn more about a company&#8217;s offering?<\/summary>\n<p>All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.<\/p>\n<\/details>\n<details>\n<summary>12. What if I change my mind about investing?<\/summary>\n<p>You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you\u2019ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: info@dealmakersecurities.com<\/p>\n<\/details>\n<details>\n<summary>13. How do I keep up with how the company is doing?<\/summary>\n<p>At a minimum, the company will be filing with the SEC and posting on it\u2019s website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.<\/p>\n<\/details>\n<details>\n<summary>14. What relationship does the company have with DealMaker Securities?<\/summary>\n<p>Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities\u2019 affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.<\/p>\n<\/details>\n<\/div>\n<div class=\"right\"><\/div>\n<p>&nbsp;<\/p>\n<\/div>\n<p><br clear=\"all\"><br \/>\n<!--close breakwrap--><\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Invest in Fisher Wallace Labs Neurotechnology for Mental Health and High Performance Recent momentum: FDA Clearance application submitted in April 2026 Pilot program launched in the U.S. Department of Veterans Affairs Invest $1502.90+ for Coupon Code for Free OAK (Rx will still be required) Invest $113+ to receive 100% Bonus Shares (i.e. buy 100 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"open","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-2","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=\/wp\/v2\/pages\/2","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2"}],"version-history":[{"count":0,"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=\/wp\/v2\/pages\/2\/revisions"}],"wp:attachment":[{"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}